Musc Foundation for Research Development

The United States Government As Represented by the Department of Veterans Affairs

Peterson, Yuri Karl

Rohrer, Baerbel

Beeson, Craig, C.

Lindsey, Christopher, C.

Craig Cano Beeson

Christopher C Lindsey

Yuri Karl Peterson

Baerbel Rohrer

Rick G Schnellmann

Giuseppe Gumina

John J Lemasters

Andaleb I Kholmukhamedov

Gary L Wright

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, promote mitochondrial biogenesis and are useful for the treatment of, for example, acute kidney injury and chronic kidney disease.

5HT1F receptor agonists and mitochondrial biogenesis

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, promote mitochondrial biogenesis and are useful for the treatment of, for example, acute kidney injury and chronic kidney disease. 

In some aspects, the present invention relates to aza-ellipticine compounds of the formula: wherein the variables are as defined herein. The application also provides novel methods of preparing aza-ellipticine compounds, methods of using the compounds, and pharmaceutical compositions thereof. 

Aza-ellipticine analogs, methods of synthesis and methods of treatment

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders. 

Oxindole compounds and pharmaceutical compositions thereof

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders

Provided herein is a fluorescent probe compound of formula (I): as well as methods of using said compound.

Fluorescent probe

Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders

Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders

Disclosed herein are compounds having Formula I, which are non-natural L-adenosine analogs. Also disclosed are their methods of making. Still further, disclosed are the uses of the disclosed compounds to treat cardiovascular disease, ischemia related injuries; and neurodegenerative diseases. The compounds disclosed herein have the formula: wherein Rand Rare, independently, H, branched or straight-chain, substituted or unsubstituted alkyl, alkenyl, alkynyl, or aryl; Ris branched or straight-chain, substituted or unsubstituted alkyl, hydroxy-alkyl, or &#x2014;C(&#x2550;O)NRR; and Rand Rare, independently, H, hydroxy, halogen, and NRR,wherein R, R, R, and Rare, independently, H, branched or straight-chain, substituted or unsubstituted alkyl, alkenyl, alkynyl, or aryl.

Growing community of inventors

Charleston, SC, United States of America

Craig Cano Beeson